FGFR4

Loading gene…

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR1 Amplification + FGFR2 Amplification + FGFR3 Amplification + FGFR4 AmplificationFGFR1 FGFR2 FGFR3 FGFR41
Erdafitinib	Malignant Neoplasm

Therapy

Cancer

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

FGFR1 Amplification + FGFR2 Amplification + FGFR3 Amplification + FGFR4 AmplificationFGFR1 FGFR2 FGFR3 FGFR41

Erdafitinib

Malignant Neoplasm

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Pediatric Pan-cancer (Columbia U, Genome Med 2016) mixed_pipseq_2017	unmapped	Ssm	15	103

Cohort

Mapped cancer

Alteration

Affected (n)

Profiled (n)

Frequency (%)

Rank in cohort

Source

Pediatric Pan-cancer (Columbia U, Genome Med 2016) mixed_pipseq_2017

unmapped

Ssm

103

FGFR4 Amplification1
Pazopanib	Ewing Sarcoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID7836 Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that responde… (full text at CIViC) PMID 28377484 · Subbiah et al., 2017 · Open in CIViC	civic

FGFR4 Amplification1

Pazopanib

Ewing Sarcoma

Predictive

Supports Sensitivity Response

submitted

EID7836

Clinical trial of soft tissue sarcoma patients found no responses to pazopanib + trametinib combination in Ewing sarcoma patients. Comparison was done to previously treated Ewing sarcoma that responde… (full text at CIViC)

PMID 28377484 · Subbiah et al., 2017 · Open in CIViC

civic

FGFR4 G636C2
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted	EID10092 The FGFR4 G636C mutation was found in a human gastric tumour. NIH/3T3 cells were transduced with WT or mutant (G636C) FGFR4. Levels of autophosphorlyation was much higher in the mutant cells. Transduc… (full text at CIViC) PMID 31601997 · Futami et al., 2019 · Open in CIViC	civic
FGFR Inhibitor ASP5878	Malignant Gastric Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID8905 Identification of an oncogenic mutation in FGFR4 in a human gastric tumour that leads to constitutive activation and sensitivity to ASP5878. PMID 31601997 · Futami et al., 2019 · Open in CIViC	civic

FGFR4 G636C2

(functional)

—UNRESOLVED

Functional

Supports Gain Of Function

submitted

EID10092

The FGFR4 G636C mutation was found in a human gastric tumour. NIH/3T3 cells were transduced with WT or mutant (G636C) FGFR4. Levels of autophosphorlyation was much higher in the mutant cells. Transduc… (full text at CIViC)

PMID 31601997 · Futami et al., 2019 · Open in CIViC

civic

FGFR Inhibitor ASP5878

Malignant Gastric Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID8905

Identification of an oncogenic mutation in FGFR4 in a human gastric tumour that leads to constitutive activation and sensitivity to ASP5878.

PMID 31601997 · Futami et al., 2019 · Open in CIViC

civic

FGFR4 G665E1
Sorafenib	Hepatocellular Carcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID13272 Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR4 G665E achieved a partial response. The same tumor also harbored FGFR2 M538I, pr… (full text at CIViC) PMID 27384874 · Kaibori et al., 2016 · Open in CIViC	civic

FGFR4 G665E1

Sorafenib

Hepatocellular Carcinoma

Predictive

Supports Sensitivity Response

submitted

EID13272

Among 45 patients with recurrent hepatocellular carcinoma treated with sorafenib, one patient whose tumor harbored FGFR4 G665E achieved a partial response. The same tumor also harbored FGFR2 M538I, pr… (full text at CIViC)

PMID 27384874 · Kaibori et al., 2016 · Open in CIViC

civic

FGFR4 N535K1
FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Rhabdomyosarcoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID8906 FGFR4 tyrosine kinase domain mutations were found among 7 of 94 (7.5%) primary human RMS tumors. The mutants K535 and E550 increased autophosphorylation, Stat3 signaling, tumor proliferation, and meta… (full text at CIViC) PMID 19809159 · Taylor et al., 2009 · Open in CIViC	civic

FGFR4 N535K1

FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074

Rhabdomyosarcoma

Predictive

Supports Sensitivity Response

submitted

EID8906

FGFR4 tyrosine kinase domain mutations were found among 7 of 94 (7.5%) primary human RMS tumors. The mutants K535 and E550 increased autophosphorylation, Stat3 signaling, tumor proliferation, and meta… (full text at CIViC)

PMID 19809159 · Taylor et al., 2009 · Open in CIViC

civic

FGFR4 Overexpression5
(prognostic)	Malignant Ovarian Neoplasm	Prognostic	B	Supports Poor Outcome	3	submitted	EID7522 In a retrospective study, the association between biomarker and prognosis in patients with advanced ovarian cancer were evaluated. High expression FGFR4 or FGF19 were associated with poor overall surv… (full text at CIViC) PMID 26323668 · Hu et al., 2015 · Open in CIViC	civic
Erlotinib	Lung Adenocarcinoma	Predictive	D	Supports Resistance	3	submitted	EID7520 In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC) PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC	civic
Erlotinib + FexagratinibCombination	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID7521 In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC) PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC	civic
Dovitinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074Substitutes	HER2-Positive Breast CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID5828 ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… (full text at CIViC) PMID 24124571 · Li et al., 2013 · Open in CIViC	civic
Ponatinib	Alveolar Rhabdomyosarcoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID7137 Indeed, cell lines expressing the highest levels of FGFR4 (above a relative level of six) were the most sensitive to ponatinib (Figure 1C, p = 0.0344). These results, therefore, suggest that increased… (full text at CIViC) PMID 24124571 · Li et al., 2013 · Open in CIViC	civic

FGFR4 Overexpression5

(prognostic)

Malignant Ovarian Neoplasm

Prognostic

Supports Poor Outcome

submitted

EID7522

In a retrospective study, the association between biomarker and prognosis in patients with advanced ovarian cancer were evaluated. High expression FGFR4 or FGF19 were associated with poor overall surv… (full text at CIViC)

PMID 26323668 · Hu et al., 2015 · Open in CIViC

civic

Erlotinib

Lung Adenocarcinoma

Predictive

Supports Resistance

submitted

EID7520

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

civic

Erlotinib + FexagratinibCombination

Lung Adenocarcinoma

Predictive

Supports Sensitivity Response

submitted

EID7521

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

civic

Dovitinib + FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074Substitutes

HER2-Positive Breast CarcinomaALIAS

Predictive

Supports Sensitivity Response

submitted

EID5828

ERBB2-positive breast cancer cell lines including MDA-MB-361 and MDA-MB-453 were found to display outlier expression of FGFR4. Targeting FGFR4 in FGFR4 overexpressing ERBB2-positive breast cancer samp… (full text at CIViC)

PMID 24124571 · Li et al., 2013 · Open in CIViC

civic

Ponatinib

Alveolar Rhabdomyosarcoma

Predictive

Supports Sensitivity Response

submitted

EID7137

Indeed, cell lines expressing the highest levels of FGFR4 (above a relative level of six) were the most sensitive to ponatinib (Figure 1C, p = 0.0344). These results, therefore, suggest that increased… (full text at CIViC)

PMID 24124571 · Li et al., 2013 · Open in CIViC

civic

FGFR4 V550E1
FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074	Rhabdomyosarcoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID8907 FGFR4 tyrosine kinase domain mutations were found among 7 of 94 (7.5%) primary human RMS tumors. The mutants K535 and E550 increased autophosphorylation, Stat3 signaling, tumor proliferation, and meta… (full text at CIViC) PMID 19809159 · Taylor et al., 2009 · Open in CIViC	civic

FGFR4 V550E1

FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074

Rhabdomyosarcoma

Predictive

Supports Sensitivity Response

submitted

EID8907

PMID 19809159 · Taylor et al., 2009 · Open in CIViC

civic

Clinical evidence (12)

Alteration frequency by cohort (100)

Linked publications (0)